Novo Holdings to buy US drug maker Catalent in $16.5bn deal.


Novo Holdings, the controlling shareholder of Novo Nordisk, has agreed to buy US drug maker Catalent in a $16.5bn cash deal.

  • Catalent, Inc.
  • 05 February 2024 13:20:00

Source: Sharecast

Novo Holdings will pay $63.50 per share, which is a premium of 16.5% to the closing Catalent share price on Friday.

Novo said it plans to sell three Catalent fill-finish sites and related assets bought in the merger to Novo Nordisk. The sites are located in Italy, the US and Belgium.

Chief executive Kasim Kutay said: "We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit.

"We are excited to support the company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the company’s full potential."


ISIN: US6701002056
Exchange: New York Stock Exchange
Sell:
$ 73.80
Buy:
$ 74.00
Change: -0.24 ( -0.32 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.